Evercore ISI initiated coverage of Dyne Therapeutics (DYN) with an Outperform rating and $46 price target Last year, the firm was “somewhat skeptical” of Dyne’s ability to successfully pursue an accelerate approval in DM1, but after seeing “strong data and positive regulatory precedents emerge,” the firm’s confidence in the AA path potential has increased and its views of their DMD commercial opportunity has increased, the analyst tells investors. With the stock having significantly pulled back, the firm finds the current valuation and path forward “extremely compelling,” says the analyst, who added the company to Evercore ISI’s SMID Core List while initiating coverage of the stock.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DYN:
- Optimistic Buy Rating for Dyne Therapeutics Driven by Promising Clinical Progress and Regulatory Advancements
- Dyne Therapeutics price target lowered to $38 from $46 at H.C. Wainwright
- Dyne Therapeutics: Strategic Advancements and Strong Financials Support Buy Rating
- Dyne Therapeutics reports Q1 EPS (81c), consensus (84c)
- Dyne Therapeutics expects cash to fund operations at least into 2H of 2026